Ovarian cancer think tank: the use of integrated artificial intelligence and computational biology in ovarian cancer diagnosis and treatment

Artificial intelligence and computational biology are rapidly advancing, offering unprecedented opportunities to transform both ovarian cancer research and clinical care. However, limited understanding of how to optimally integrate the information these tools provide with existing clinical data has led to a lag in integration. This commentary emerges from a unique and focused ovarian cancer research conference that explored how these emerging tools and technologies (i.e., artificial intelligence and computational biology) can be leveraged to address questions in pathology, develop new paradigms of tumor biology, and integrate precision medicine into clinical management of complex and rare subtypes of ovarian cancer. We highlight key ways in which systematic integration of Artificial intelligence (AI) and computational tools can be leveraged to improve outcomes in ovarian cancer as well as the limitations and risks of their application.

Computational biology; Ovarian cancer; Artificial intelligence; Tumor microenvironment; Pathobiology; Machine learning; Carcinosarcoma

[1] Akazawa M, Hashimoto K. Artificial intelligence in gynecologic cancers: current status and future challenges—a systematic review. Artificial Intelligence in Medicine. 2021; 120: 102164.

[2] Jiang Y, Wang C, Zhou S. Artificial intelligence-based risk stratification, accurate diagnosis and treatment prediction in gynecologic oncology. Seminars in Cancer Biology. 2023; 96: 82–99.

[3] Bhardwaj V, Sharma A, Parambath SV, Gul I, Zhang X, Lobie PE, et al. Machine learning for endometrial cancer prediction and prognostication. Frontiers in Oncology. 2022; 12: 852746.

[4] Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC, Mu J, et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Medicine. 2023; 12: 11149–11165.

[5] Hippen AA, Omran DK, Weber LM, Jung E, Drapkin R, Doherty JA, et al. Performance of computational algorithms to deconvolve heterogeneous bulk ovarian tumor tissue depends on experimental factors. Genome Biology. 2023; 24: 239.

[6] Geistlinger L, Oh S, Ramos M, Schiffer L, LaRue RS, Henzler CM, et al. Multiomic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma. Cancer Research. 2020; 80: 4335–4345.

[7] Nakamura K, Aimono E, Tanishima S, Imai M, Nagatsuma AK, Hayashi H, et al. Intratumoral genomic heterogeneity may hinder precision medicine strategies in patients with serous ovarian carcinoma. Diagnostics. 2020; 10: 200.

[8] Ivich A, Davidson NR, Grieshober L, Li W, Hicks SC, Doherty JA, et al. Missing cell types in single-cell references impact deconvolution of bulk data but are detectable. Genome Biology. 2025; 26: 86.

[9] Davidson NR, Zhang F, Greene CS. BuDDI: bulk deconvolution with domain invariance to predict cell-type-specific perturbations from bulk. PLOS Computational Biology. 2025; 21: e1012742.

[10] Gopinatha Pillai MS, Shaw P, Dey Bhowmik A, Bhattacharya R, Rao G, Dhar Dwivedi SK. Uterine carcinosarcoma: unraveling the role of epithelial-to-mesenchymal transition in progression and therapeutic potential. The FASEB Journal. 2024; 38: e70132.

[11] Peixoto L, Abel T. The role of histone acetylation in memory formation and cognitive impairments. Neuropsychopharmacology. 2013; 38: 62–76.

[12] Zhang W, Aubert A, Gomez de Segura JM, Karuppasamy M, Basu S, Murthy AS, et al. The nucleosome remodeling and deacetylase complex NuRD is built from preformed catalytically active sub-modules. Journal of Molecular Biology. 2016; 428: 2931–2942.

[13] Jordan KR, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, et al. The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval. Clinical Cancer Research. 2020; 26: 6362–6373.

[14] Yu P, Xu H, Hu X, Deng C. Leveraging generative AI and large language models: a comprehensive roadmap for healthcare integration. Healthcare. 2023; 11: 2776.

[15] Orsulic S, John J, Walts AE, Gertych A. Computational pathology in ovarian cancer. Frontiers in Oncology. 2022; 12: 924945.

[16] Lan C, Li J, Huang X, Heindl A, Wang Y, Yan S, et al. Stromal cell ratio based on automated image analysis as a predictor for platinum-resistant recurrent ovarian cancer. BMC Cancer. 2019; 19: 159.

[17] Lou E, Vogel RI, Hoostal S, Klein M, Linden MA, Teoh D, et al. Tumor-stroma proportion as a predictive biomarker of resistance to platinum-based chemotherapy in patients with ovarian cancer. JAMA Oncology. 2019; 5: 1222–1224.

[18] Gertych A, Walts AE, Cheng K, Liu M, John J, Lester J, et al. Dynamic changes in the extracellular matrix in primary, metastatic, and recurrent ovarian cancers. Cells. 2022; 11: 3769.

[19] Xu AM, Haro M, Walts AE, Hu Y, John J, Karlan BY, et al. Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma. Science Advances. 2024; 10: eadk8805.

[20] Davidson BA, Turner TB, Kim KH, Cass I, Calat L, McGwin G, et al. SGO and the elephant that is still in the room: wellness, burnout and gynecologic oncology. Gynecologic Oncology. 2022; 167: 354–359.

[21] West CP, Dyrbye LN, Shanafelt TD. Physician burnout: contributors, consequences and solutions. Journal of Internal Medicine. 2018; 283: 516–529.

[22] Murphy A, Bowen K, Naqa IME, Yoga B, Green BL. Bridging health disparities in the data-driven world of artificial intelligence: a narrative review. Journal of Racial and Ethnic Health Disparities. 2025; 12: 2367–2379.

[23] Ayers JW, Poliak A, Dredze M, Leas EC, Zhu Z, Kelley JB, et al. Comparing physician and artificial intelligence chatbot responses to patient questions posted to a public social media forum. JAMA Internal Medicine. 2023; 183: 589–596.

[24] Tierney AA, Gayre G, Hoberman B, Mattern B, Ballesca M, Kipnis P, et al. Ambient artificial intelligence scribes to alleviate the burden of clinical documentation. NEJM Catalyst. 2024; 5: CAT.23.0404.

[25] Agatstein K. Chart review is dead; Long live chart review: how artificial intelligence will make human review of medical records obsolete, one day. Population Health Management. 2023; 26: 438–440.

[26] Koenecke A, Choi AS, Mei KX, Schellmann H, Sloane M. Careless whisper: speech-to-text hallucination harms, FAccT ‘24: Proceedings of the 2024 ACM Conference on Fairness, Accountability, and Transparency. FAccT ’24, 03–06 June 2024, Rio de Janeiro, Brazil. Association for Computing Machinery, New York, NY, USA. 2024.

[27] Fastowski A, Kasneci G. Understanding knowledge drift in LLMs through misinformation. IDiscovering drift phenomena in evolving landscapes: First International Workshop. DELTA 2024, Barcelona, Spain, 126 August 2024. Springer-Verlag: Heidelberg, Berlin. 2024.

[28] Giles BM, Culp-Hill R, Law RA, Nichols CM, Goldberg M, Radnaa E, et al. Utilizing serum-derived lipidomics with protein biomarkers and machine learning for early detection of ovarian cancer in the symptomatic population. Cancer Research Communications. 2025; 5: 1516–1529.

[29] Medina JE, Annapragada AV, Lof P, Short S, Bartolomucci AL, Mathios D, et al. Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers. Cancer Discovery. 2025; 15: 105–118.

[30] Ivansson E, Hedlund Lindberg J, Stålberg K, Sundfeldt K, Gyllensten U, Enroth S. Large-scale proteomics reveals precise biomarkers for detection of ovarian cancer in symptomatic women. Scientific Reports. 2024; 14: 17288.

[31] Crispin-Ortuzar M, Woitek R, Reinius MAV, Moore E, Beer L, Bura V, et al. Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer. Nature Communications. 2023; 14: 6756.

[32] Bi Q, Ai C, Qu L, Meng Q, Wang Q, Yang J, et al. Foundation model-driven multimodal prognostic prediction in patients undergoing primary surgery for high-grade serous ovarian cancer. npj Precision Oncology. 2025; 9: 114.

[33] Yang Z, Zhang Y, Zhuo L, Sun K, Meng F, Zhou M, et al. Prediction of prognosis and treatment response in ovarian cancer patients from histopathology images using graph deep learning: a multicenter retrospective study. European Journal of Cancer. 2024; 199: 113532.